Type 2 Diabetes

Opposition to any weight loss approach that fails to take into account overall health considerations.

Researchers have shown that a drug can simultaneously block three of the major biochemical pathways responsible for the blood-vessel damage that causes serious diabetic complications.

Obesity cannot be easily explained as simply a breakdown in willpower.

Research into the insulin-producing beta cell of the pancreas may offer a key into the development of diabetes mellitus.

Supplementing the diet with a certain fatty acid may lead to better weight control and disease management in diabetics.

Adding antioxidants to therapy improves drug's ability to reduce blood sugar.

Researchers suggest that they have a technique that may be used to detect a group of self-destructive cells involved in autoimmune disorders, which may increase ability to predict the development of diabetes.

Through the study of fat storage in nematode worms, researchers have formulated a new model for understanding the mechanisms of obesity and diabetes in humans.

A collaboration of scientists has developed a new mouse model of lipoatrophic diabetes, and highlighted leptin therapy as a successful tool to combat this rare form of type II diabetes.

Researchers have successfully tested micro-sized gelatin particles that may one day deliver therapeutic genes to treat a type of kidney disease.

Longer dialysis treatment and use of a highly permeable artificial kidney may not improve survival rates or reduce hospitalization of patients with end-stage kidney disease.

FDA has cleared the first over-the-counter test that measures glycated hemoglobin in people with diabetes.

A team led by Deborah J. Good has identified a gene that appears to play a role in obesity, physical activity, and sex behaviors in mice.

Black and Hispanic children face higher risk than white children for insulin resistance-a stepping-stone to type 2 diabetes-regardless of whether they are heavy or thin, according to researchers.

Researchers have found that drugs used to prevent blood coagulation appear to have different effects in heart patients with diabetes.

Up to $2.3 billion in total health care cost savings could be achieved in just three years if Americans with type 2 diabetes and kidney disease received treatment with irbesartan.